Standard BioTools Inc. LAB NASDAQ

Standard BioTools Inc. (LAB) reported declining year-over-year revenue growth of -51.1% through 2025-12 (TTM revenue vs prior-year TTM). Net income showed exceptional earnings expansion of +46.1% YoY, reaching $19M in the latest quarter. The net profit margin is 598.5%, which is exceptional. the company was profitable in 1 out of the last 4 quarters. The gross margin is 57.3% (high), up 9.3pp vs the prior year. With a market cap data available, MOAT composite score of 50/100 (moderate competitive position).

Criteria proven by this page:

• GROWTH (65/100, Partial) — growth is present but not consistently above 5% across both metrics
• PAST (0/100, Fail) — the company has frequently reported losses. Looking at the full 21-year annual history, the company was profitable in 0 of 21 years — a mixed long-term record
• INCOME (10/100, Pass) — proves strong profitability and pricing power
• MOAT (50/100, Partial) — some competitive advantages are present but not dominant

Overall SharesGrow Score: 51/100 with 3/7 criteria passed.